Parmax Pharma Stock Plummets to New 52-Week Low at Rs. 29.9

Parmax Pharma has reached a new 52-week low, hitting Rs. 29.9 on October 3, 2025. This marks a significant decline for the microcap company, which has been underperforming in the pharmaceuticals and biotechnology sector. Over the past five days, Parmax Pharma has seen a consecutive fall, resulting in an 11.88% decrease in returns during this period.
The stock's performance today has lagged behind the sector by 1.91%. Parmax Pharma is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent downward trend. Over the past year, the stock has generated a return of -28.96%, contrasting sharply with the Sensex's performance of -1.87%.

Financial metrics reveal a challenging landscape for Parmax Pharma, with net sales declining by 43.96% in the latest six months and a negative EBITDA indicating financial strain. The company's ability to service its debt remains weak, further complicating its market position. As the stock continues to navigate these difficulties, it reflects broader trends within the microcap segment of the market.